| Autor: |
Begna, Kebede H., Kittur, Jaya, Yui, Jennifer, Gangat, Naseema, Patnaik, Mrinal M., Al‐Kali, Aref, Elliott, Michelle A., Hogan, William J., Litzow, Mark R., Hook, Christopher C., Wolanskyj, Alexandra P., Howard, Matthew T., Hanson, Curtis A., Ketterling, Rhett P., Pardanani, Animesh D., Tefferi, Ayalew |
| Předmět: |
|
| Zdroj: |
British Journal of Haematology; Nov2021, Vol. 195 Issue 3, p413-416, 4p |
| Abstrakt: |
Summary: Institutional database search (1999–2020) for acute myeloid leukaemia (AML) identified 109 cases of myeloid sarcoma (MS), of which 19 were isolated and presented de novo. The latter displayed longer survival (median 78 months), compared to MS with synchronous intramedullary AML (n = 32; median 16 months) and de novo AML without MS (n = 729; median 22 months; P = 0·13). However, the difference in survival was no longer apparent after accounting for bone marrow cytogenetic risk status (P = 0·67). Treatment‐induced MS tumour resolution was not affected by the presence of intramedullary disease (P = 0·61). The current study clarifies the prognosis of de novo isolated MS, in the context of AML. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
Plný text